+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Antigenic Peptides Market - Global Forecast 2026-2032- Product Image
Multiple Antigenic Peptides Market - Global Forecast 2026-2032- Product Image
New

Multiple Antigenic Peptides Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118360
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Antigenic Peptides Market grew from USD 248.27 million in 2025 to USD 267.74 million in 2026. It is expected to continue growing at a CAGR of 6.99%, reaching USD 398.50 million by 2032.

A strategic overview of multiple antigenic peptides emphasizing design versatility, immunological relevance, and downstream integration into translational research workflows

Multiple antigenic peptides represent a pivotal enabling technology for immunology, diagnostics, and therapeutic discovery, offering a modular route to present defined epitopes for targeted immune engagement. The design flexibility of branched peptide constructs permits presentation of multiple antigenic determinants in a single synthetic molecule, enhancing immunogenicity while reducing the complexity and variability associated with whole-protein antigens. This capability has driven cross-disciplinary interest from academic laboratories studying immune mechanisms to industry teams developing vaccines, diagnostic assays, and peptide-based therapeutics.

As biochemical techniques and solid- and liquid-phase peptide synthesis methods have matured, researchers have gained finer control over sequence fidelity, branching chemistry, and conjugation strategies. These advances, combined with increasingly sensitive analytical methods, have widened the window for application and scaled experimental approaches from discovery to preclinical validation. The cumulative effect is a technology platform that is both scientifically robust and operationally adaptable, primed for deeper integration into translational pipelines across immunology, proteomics, and clinical assay development.

How converging advances in synthesis, analytics, and regulatory engagement are reshaping peptide antigen design and accelerating translational adoption

The landscape for multiple antigenic peptides is shifting in response to scientific innovation, regulatory attention, and evolving industry priorities that together are transforming how antigen design is conceived and deployed. Advances in synthetic chemistry and high-throughput screening approaches have shortened design cycles and increased the precision with which epitopes are selected and presented. Concurrently, improved mass spectrometry and sequencing methods have strengthened the ability to characterize peptide constructs and their biological interactions, enabling more confident translation from bench findings into applied contexts.

Another important shift is the growing emphasis on platform approaches that enable modular reuse of validated peptide scaffolds across distinct applications. This modularity reduces developmental friction and supports parallel exploration in diagnostics, vaccine programs, and therapeutic discovery. Regulatory agencies are increasingly engaging with peptide-based modalities, prompting sponsors to emphasize robust characterization, reproducibility, and manufacturing controls earlier in development. Taken together, these trends are fostering a more integrated ecosystem in which innovation, standardization, and translational focus reinforce one another to accelerate practical adoption.

Assessing how tariff changes and trade policy pressures are prompting strategic supply chain adaptations and resilience planning across peptide synthesis ecosystems

Tariff dynamics and international trade policy have direct implications for the supply chains that underpin peptide synthesis, reagent availability, and contract research operations. Changes in import tariffs can alter the landed cost of critical raw materials such as protected amino acids, specialty resins, and coupling reagents, creating incentives for firms to reassess supplier footprints and sourcing strategies. In response, organizations are increasingly conducting scenario planning to understand supplier diversification, inventory strategies, and nearshoring options that reduce exposure to tariff volatility.

Beyond cost considerations, tariff-driven supply shifts can influence lead times and supplier selection, prompting companies to qualify secondary vendors and invest in local manufacturing capabilities. These adaptations often accelerate investments in reagent standardization and in-house capabilities for solid-phase and liquid-phase peptide synthesis to maintain continuity of operations. At the program level, procurement and R&D leaders are balancing short-term operational resilience with long-term supplier relationships, ensuring that research and development throughput remains robust despite evolving trade conditions and customs regimes.

A multidimensional segmentation framework explaining how type, application, end use, synthesis technology, and distribution channels determine strategic product positioning

Segmentation analysis reveals differentiated demand drivers across product configurations, application domains, end users, synthesis technologies, and distribution pathways. Based on Type, market is studied across 16Map, 2Map, 4Map, and 8Map, reflecting varied branching architectures that influence potency, manufacturability, and analytical requirements. Based on Application, market is studied across Basic Research, Diagnostics, Therapeutic Applications, and Vaccine Development, with Basic Research further studied across Immunology and Proteomics, Diagnostics further studied across Autoimmune Disease and Infectious Disease, Therapeutic Applications further studied across Monoclonal Antibody Development and Peptide Based Therapies, and Vaccine Development further studied across Animal Vaccines and Human Vaccines; these application strata clarify where academic inquiry translates into commercial opportunity and where translational bottlenecks may arise.

Based on End Use, market is studied across Academic Institutes, Biotechnology Companies, and Pharmaceutical Companies, which highlights differences in procurement processes, regulatory requirements, and timelines from discovery to development. Based on Technology, market is studied across Liquid Phase and Solid Phase, the Solid Phase further studied across Boc Synthesis and Fmoc Synthesis, illustrating trade-offs between scale, protection chemistries, and environmental or operational preferences. Based on Distribution Channel, market is studied across Direct Sales, Distributors, and E Commerce, demonstrating varied go-to-market models and channel economics. These segmentation lenses together map pathways for product positioning, partnering strategies, and targeted commercialization efforts.

Regional characteristics and strategic considerations that shape research partnerships, manufacturing placement, and regulatory engagement across global peptide ecosystems

Regional dynamics shape strategic priorities for research funding, manufacturing investments, and collaborative networks that support multiple antigenic peptide development. In the Americas, strong translational links between academic centers, biotech clusters, and contract development organizations create a vibrant environment for moving peptide platforms from discovery to preclinical validation. In Europe, Middle East & Africa, regulatory harmonization initiatives, public-private partnerships, and well-established clinical research networks support cross-border collaboration, while regional policy frameworks influence manufacturing site selection and pipeline prioritization. In Asia-Pacific, rapidly expanding biopharma investment, growing contract manufacturing capacity, and a large talent pool in peptide chemistry and immunology accelerate local innovation and create opportunities for scale.

These regional characteristics inform corporate strategies for talent deployment, partner selection, and capital allocation. Companies with a global footprint are tailoring R&D hubs and supply chains to leverage regional strengths-concentrating early-stage discovery where academic partnerships are strongest, pursuing scale manufacturing in regions with favorable capacity and cost structures, and aligning regulatory engagement with regions that offer predictable pathways for clinical development. An integrated, region-aware approach therefore optimizes both operational resilience and the potential for collaborative scientific advancement.

Competitive strategies and operational models that distinguish innovators, integrators, and collaborators in peptide antigen design and delivery

Leading organizations operating in the multiple antigenic peptide space demonstrate differentiated strategies across innovation, manufacturing, and commercialization. Some market participants prioritize deep technical capability in peptide chemistry and analytical characterization, investing in platform development that standardizes branching architectures and enhances reproducibility. Others concentrate on vertical integration, securing raw materials supply, and expanding in-house synthesis capacity to shorten lead times and exercise tighter quality control. Collaborative models also play a central role, with academic-industry partnerships accelerating early-stage validation and contract organizations enabling flexible scale-up.

Competitive differentiation often rests on the ability to pair high-quality peptide constructs with robust data packages that support translational decision-making. Companies that combine rigorous process development with clear value propositions for diagnostics, vaccine adjuvancy, or therapeutic conjugation are better positioned to win partnerships and clinical collaborations. Finally, firms that proactively address regulatory expectations and manufacturing standards create a lower-friction path to downstream development, reinforcing credibility with pharmaceutical sponsors and institutional customers.

High-impact strategic priorities and tangible actions that industry leaders can adopt to fortify platforms, accelerate development, and mitigate supply chain vulnerabilities

Industry leaders should prioritize strategic investments that enhance platform robustness, supply resilience, and translational alignment with clinical needs. Strengthening in-house capabilities for both solid-phase and liquid-phase synthesis will reduce vulnerability to external supply shocks and accelerate iteration cycles. Equally important is the establishment of standardized characterization protocols and quality-by-design practices that ease regulatory interactions and support consistent performance across batches.

Leaders should also cultivate targeted partnerships with academic centers, CROs, and specialized CMOs to bridge discovery and manufacturing scale, enabling faster validation of candidate constructs and flexible production capacity. Commercially, firms must refine channel strategies that match product complexity to customer needs, blending direct engagement for enterprise customers with distributor and e-commerce options for consumables and standardized kits. Finally, dedicating cross-functional teams to scenario planning around trade policy, raw-material supply, and manufacturing footprints will position organizations to respond quickly to external disruptions while preserving development momentum.

A rigorous multi-source research approach combining expert interviews, technical literature synthesis, and patent and regulatory analysis to validate insights and implications

The research methodology underpinning this executive summary synthesizes qualitative and quantitative evidence from peer-reviewed literature, patent landscapes, regulatory guidance, primary interviews with domain experts, and analysis of commercial practice. Information was triangulated across technical publications and vendor technical datasheets to validate claims about synthesis methods, analytical techniques, and application-specific requirements. Expert interviews provided context on operational considerations, procurement behavior, and translational bottlenecks, while patent and literature reviews highlighted recent technological innovations and emerging use cases.

To ensure analytical rigor, data points were cross-checked for consistency and relevance, and interpretation prioritized mechanistic explanations over speculative assertions. Where appropriate, industry practices and technical trends were contextualized within broader shifts in peptide chemistry, manufacturing technology, and regulatory expectations. This approach supports conclusions that are robust, actionable, and relevant for decision-makers seeking to translate scientific opportunity into operational plans.

Synthesis of strategic implications underscoring how science, operations, and collaboration must align to realize the translational promise of peptide-based antigen platforms

Multiple antigenic peptides occupy a strategic intersection of synthetic chemistry, immunology, and translational development, with applications that span basic discovery through diagnostics, vaccines, and therapeutic modalities. The technology’s modularity and evolving synthesis capabilities make it well suited to address current needs in epitope-focused vaccine design, assay specificity for autoimmune and infectious disease diagnostics, and to support antibody discovery and peptide-based therapeutic strategies. Continued advances in analytical characterization, process reproducibility, and platform standardization will determine the pace at which academic discoveries move into clinical or commercial use.

Organizations that proactively integrate synthesis expertise, regulatory foresight, and supply chain resilience into their development strategies will be best placed to capitalize on these opportunities. Cross-sector collaboration, combined with disciplined quality management and a focus on translational endpoints, will accelerate the conversion of laboratory promise into products that meet clinical and market requirements. The conclusion is clear: strategic, coordinated investment across science, operations, and commercialization is essential to unlock the full potential of multiple antigenic peptides.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of synthetic multiple antigenic peptide platforms for personalized cancer immunotherapies
5.2. Integration of artificial intelligence models to predict epitope binding affinity in multiple antigenic peptide design
5.3. Expansion of multiple antigenic peptide based serological diagnostics for emerging infectious disease surveillance
5.4. Development of modular peptide scaffolds to enhance multivalent immune responses in vaccine candidates
5.5. Regulatory harmonization initiatives accelerating clinical approval pathways for multiple antigenic peptide therapeutics
5.6. Strategic partnerships driving scale up of GMP compliant manufacturing processes for multiple antigenic peptides
5.7. Advances in nanoparticle and adjuvant delivery systems improving stability and bioavailability of multiple antigenic peptides
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Antigenic Peptides Market, by Type
8.1. Introduction
8.2. 16Map
8.3. 2Map
8.4. 4Map
8.5. 8Map
9. Multiple Antigenic Peptides Market, by Application
9.1. Introduction
9.2. Basic Research
9.2.1. Immunology
9.2.2. Proteomics
9.3. Diagnostics
9.3.1. Autoimmune Disease
9.3.2. Infectious Disease
9.4. Therapeutic Applications
9.4.1. Monoclonal Antibody Development
9.4.2. Peptide Based Therapies
9.5. Vaccine Development
9.5.1. Animal Vaccines
9.5.2. Human Vaccines
10. Multiple Antigenic Peptides Market, by End Use
10.1. Introduction
10.2. Academic Institutes
10.3. Biotechnology Companies
10.4. Pharmaceutical Companies
11. Multiple Antigenic Peptides Market, by Technology
11.1. Introduction
11.2. Liquid Phase
11.3. Solid Phase
11.3.1. Boc Synthesis
11.3.2. Fmoc Synthesis
12. Multiple Antigenic Peptides Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Distributors
12.4. E Commerce
13. Americas Multiple Antigenic Peptides Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Multiple Antigenic Peptides Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Multiple Antigenic Peptides Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Bachem AG
16.3.4. GenScript Biotech Corporation
16.3.5. Sangon Biotech (Shanghai) Co., Ltd.
16.3.6. GL Biochem (Shanghai) Ltd.
16.3.7. CPC Scientific Inc.
16.3.8. JPT Peptide Technologies GmbH
16.3.9. Peptide Synthetics Ltd.
16.3.10. Bio-Synthesis Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MULTIPLE ANTIGENIC PEPTIDES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MULTIPLE ANTIGENIC PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MULTIPLE ANTIGENIC PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MULTIPLE ANTIGENIC PEPTIDES MARKET: RESEARCHAI
FIGURE 26. MULTIPLE ANTIGENIC PEPTIDES MARKET: RESEARCHSTATISTICS
FIGURE 27. MULTIPLE ANTIGENIC PEPTIDES MARKET: RESEARCHCONTACTS
FIGURE 28. MULTIPLE ANTIGENIC PEPTIDES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MULTIPLE ANTIGENIC PEPTIDES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 16MAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 16MAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 2MAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 2MAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 4MAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 4MAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 8MAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY 8MAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY PROTEOMICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY MONOCLONAL ANTIBODY DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY MONOCLONAL ANTIBODY DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY PEPTIDE BASED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY PEPTIDE BASED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY ANIMAL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY ANIMAL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY LIQUID PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BOC SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BOC SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY FMOC SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY FMOC SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY E COMMERCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 125. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 126. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 127. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 130. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 131. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 132. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 133. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 134. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 135. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 136. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 137. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 138. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 139. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 140. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 141. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 142. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 143. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. CANADA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 148. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 149. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 150. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 151. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 156. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 157. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 160. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 161. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. MEXICO MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 248. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 249. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 252. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 253. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 254. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 255. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 256. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 257. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 258. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 259. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 260. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 261. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 262. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 263. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 264. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 265. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. GERMANY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 268. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 269. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 272. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 273. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 274. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 275. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 276. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 277. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 278. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 279. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 280. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 281. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 282. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 283. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 284. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 285. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. FRANCE MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY VACCINE DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY SOLID PHASE, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. ITALY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 308. ITALY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 309. ITALY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 310. ITALY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 311. ITALY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
TABLE 312. ITALY MULTIPLE ANTIGENIC PEPTIDES MARKET SIZE, BY BASIC RESEARCH

Companies Mentioned

  • AAPPTec, LLC
  • ABclonal
  • Advanced Peptides
  • Almac Sciences
  • Alta Bioscience
  • AmbioPharm
  • AnaSpec (part of the KANEKA Eurogentec network)
  • Auspep
  • Bachem
  • BCN Peptides
  • Bio-Synthesis, Inc.
  • Biomatik
  • Biosynth (includes Cambridge Research Biochemicals)
  • CD Formulation
  • Chempep
  • CordenPharma
  • CPC Scientific
  • CSBio
  • GenScript
  • PolyPeptide Group

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 267.74 Million
Forecasted Market Value ( USD ) by 2032 $ 398.5 Million
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Reports

Peptide Vaccine for Tumor Market - Global Forecast 2025-2030 - Product Image

Peptide Vaccine for Tumor Market - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Peptide-Carrier Protein Conjugates Market - Global Forecast 2026-2032 - Product Image

Peptide-Carrier Protein Conjugates Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Covid-19 - Pipeline Insight, 2025 - Product Image

Covid-19 - Pipeline Insight, 2025

  • Drug Pipelines
  • 450 Pages
  • Global
From
Rabies Infection - Pipeline Insight, 2025 - Product Image

Rabies Infection - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
TCR Therapy Drug Pipeline Analysis Report 2025 - Product Image

TCR Therapy Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.